CN105232547A - Anti-diabetic oral drug composition - Google Patents
Anti-diabetic oral drug composition Download PDFInfo
- Publication number
- CN105232547A CN105232547A CN201510767710.1A CN201510767710A CN105232547A CN 105232547 A CN105232547 A CN 105232547A CN 201510767710 A CN201510767710 A CN 201510767710A CN 105232547 A CN105232547 A CN 105232547A
- Authority
- CN
- China
- Prior art keywords
- base
- biphenyl
- dihydro
- fluoro
- cyclopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses an anti-diabetic oral drug composition which comprises 10-20 mg of 5-(3-hydroxyl-7-propoxynaphthalene-2-yl)-1,1-dioxo-[1,2,5] thiadiazole alkane-3-dipotassium salt, 20-30 mg of 3-cyclopropyl-3-(2-(2'-fluorine-5'-methoxy-[1,1'-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[2,3-b]ppridine-7-yl)-2-propionic acid, 200-300 mg of microcrystalline cellulose, 10-25 mg of cross-linked sodium carboxymethylcellulose and 1-8 mg of magnesium stearate. By compounding two different types of actives, on the premise that the identical treatment effect is achieved, the use amount of the actives of the drug is decreased by a half at least.
Description
Technical field
The present invention relates to medical art, be specifically related to a kind of diabetes combination of oral medication.
Background technology
The metabolic disease of diabetes to be one group with hyperglycemia be feature.Hyperglycemia be then due to defect of insulin secretion or its biological agent impaired, or both have concurrently and cause.Long-standing hyperglycemia during diabetes, causes various tissue, particularly eye, kidney, heart, blood vessel, neural chronic lesion, dysfunction.
The generally acknowledged form of usual existence two kinds of diabetes.In type 1 diabetes or insulin-dependent diabetes (IDDM), patient produces seldom or does not have insulin, regulates the hormone of glucose application.In type 2 diabetes mellitus or noninsulindependent diabetes (NIDDM), still produce insulin in the body.There is in the stimulation glucose of the patient suffering from type 2 diabetes mellitus in main insulin-sensitive tissue (it is muscle, liver and fatty tissue) and lipid metabolism the toleration to insulin action.These patients have the insulin of common level usually, and may have hyperinsulinemia (plasma insulin level of rising), because they compensate by the insulin of secretion rise the insulin effects reduced.Insulin resistance can not be caused by the Insulin receptor INSR reducing quantity but be caused by the rear Insulin receptor INSR binding deficient understood not yet completely substantially.This lacks and to cause in the oxidation of glucose in the activation of the insulin-mediated of inadequate picked-up, muscle and storage and fatty tissue glucose in lipidolysis and liver to produce to the responding ability of insulin and the suppression of insufficient insulin-mediated of secretion.
Current Remedies for diabetes is maintaining treatment effect, many employing 100mg active matter oral doses, and needs daily repeatedly to take.Due to the side effect of active matter, other health hazards are caused to patient, meanwhile, due to the increase of dosage, also make medicine cost increase, cause the raising for the treatment of cost.
Summary of the invention
The object of the invention is to propose a kind of diabetes combination of oral medication, its composite by two kinds of dissimilar active matters, under the prerequisite reaching identical therapeutic effect, the use amount of the active matter of medicine is reduced at least 1/2.
For reaching this object, the present invention by the following technical solutions:
A kind of diabetes combination of oral medication, it comprises following component:
(1) 5-(3-hydroxyl-7-propoxyl group naphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt of 10-20mg
(2) 3-cyclopropyl-3-(2-(2 '-fluoro-5 '-methoxyl group-[1,1 '-biphenyl]-4-base)-3,4-dihydro-2H-pyrans also [2, the 3-b] pyridin-7-yl) propanoic acid of 20-30mg
(3) 200-300mg microcrystalline Cellulose,
(4) 10-25mg cross-linking sodium carboxymethyl cellulose, and
(5) 1-8mg magnesium stearate.
Described 5-(3-hydroxyl-7-propoxyl group naphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt and 3-cyclopropyl-3-(2-(2 '-fluoro-5 '-methoxyl group-[1,1 '-biphenyl]-4-base)-3,4-dihydro-2H-pyrans also [2,3-b] pyridin-7-yl) ratio of propanoic acid is less than 1.
Detailed description of the invention
The present invention is described pharmaceutical composition of the present invention by following embodiment.
Embodiment 1
I.5-(3-hydroxyl-7-propoxyl group naphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt
Step 1
3-hydroxyl-7-propoxyl group naphthalene-2-propyl formate
3.0g (14.7mmol) 3,7-dihydroxy naphthlene-2-formic acid is added in the suspension of 1.6g (29.6mmol) Feldalat NM in DMA (30mL).By mixture in stirring at room temperature 1 hour, then add 5.05g (29.7mmol) propyl iodide, continue stirring 48 hours.By in mixture impouring water, use 2NHCl acidify.Be extracted with ethyl acetate mixture, by (3 ×) water and saline (1 ×) washing organic facies.Use dried over sodium sulfate solution, under reduced pressure except desolventizing.Residual oil thing carries out purification by flash chromatography dichloromethane, elutes title compound, isolates as yellow oil.MS(M-1)：287。
Step 2
3-benzyloxy-7-propoxyl group naphthalene-2-propyl formate
0.98g (5.73mmol) benzyl bromide a-bromotoluene is added in 1.5g (5.21mmol) 3-hydroxyl-7-propoxyl group naphthalene-2-propyl formate and the mixture of 1.08g (7.81mmol) potassium carbonate in DMF (15mL).By mixture in stirring at room temperature 48 hours, then in impouring water.Be extracted with ethyl acetate mixture, wash organic facies with water (3x) and saline (1x).Use dried over sodium sulfate solution, under reduced pressure except desolventizing.Residual oil thing uses dichloromethane to carry out purification by flash chromatography, elutes title compound, is separated into yellow oil.
Step 3
3-benzyloxy-7-propoxyl group naphthalene-2-formic acid
In the solution of 680mg (1.8mmol) 3-benzyloxy-7-propoxyl group naphthalene-2-propyl formate in EtOH (15mL), add 2.0mL1.0NNaOH, then mixture is stirred 3 hours in 60 DEG C.Under reduced pressure except desolventizing, residual solid is soluble in water.Use MTBE wash solution, with 1NHCl acidify aqueous phase.Filtration gained precipitates, and washing with water, drying under reduced pressure, obtain title compound, is white solid, mp125-128 ° of .MS (M-1): 335.
5-(3-hydroxyl-7-propoxyl group naphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt
In accordance with known methods, title compound is obtained, mp250-255 ° by 3-benzyloxy-7-propoxyl group naphthalene-2-formic acid.
1h-NMR (DMSO-d6: δ 7.88 (s, 1H), 7.54 (d, J=9.04Hz, 1H), 7.13 (s, 1H), 7.12 (d, J=2.64Hz, 1H), 6.98 (dd, J=9.04 and 2.64Hz, 1H), 4.19 (s, 2H), 3.98 (t, 2H), 1.75 (m, 2H), 1.00 (t, 3H) .MS (M-1): 335.
II.3-cyclopropyl-3-(2-(2 '-fluoro-5 '-methoxyl group-[1,1 '-biphenyl]-4-base)-3,4-dihydro-2H-pyrans also [2,3-b] pyridin-7-yl) propanoic acid
The chloro-3-of step 1:6-(hydroxymethyl) pyridine-2 (1H)-one
LAH (0.547g, 14.40mmol) is added in cooling (-78 DEG C) THF (10mL) solution of 6-chlorine-2-hydroxyl nicotinic acid (1g, 5.76mmol).After 1h, this reaction is heated to 60 DEG C.After 1h, make this reaction be cooled to room temperature and by adding 0.5mL water, then 0.5mL15%NaOH, then 1mL shrend is gone out Feezer.Vigorous stirring gained mixture 1h, then distributes between water/DCM.Merge organic layer, dry (NaSO) is also concentrated.By HPLC (ISCO80g, 0 to 100%EtOAc) purification gained residue to provide title compound.
1HNMR(500MHz，DMSO-d6)：7.59(d，1H)，6.68(d，1H)，4.90(br，2H).
The chloro-2-of step 2:7-(the fluoro-5'-methoxyl group of 2'--[1,1'-biphenyl]-4-base)-3,4-dihydro-2H-pyrans also [2,3-b] pyridine
To the chloro-3-of 6-(hydroxymethyl) pyridine-2 (1H)-one (858mg, 3.76mmol), the fluoro-5-methoxyl group of 2--4'-vinyl-1,1'-biphenyl (300mg, 1.880mmol), lithium perchlorate (250mg, 2.350mmol), with add water (423 μ l, 23.50mmol) in Nitrocarbol. (3mL) solution of montorillonite clay K10 (300mg).Heat block heats gained serosity to 80 DEG C in sealed vial.After 16h, this reactant mixture is made to be cooled to room temperature.Then filter this reaction (MgSO) and concentrate.By HPLC (ISCO120g, 0 to 50%EtOAc/Hex) purification gained residue to provide title compound.
1HNMR(500MHz，CHCl
3-d)：7.59(d，2H)，7.50(d，2H)，7.40(d，1H)，7.09(t，1H)，6.95(m，2H)，6.82(d，1H)，5.35(d，1H)，3.81(s，3H)，2.98(m，1H)，2.80(d，1H)，2.32(d，1H)，2.12(q，1H).
Step 3:(2-(the fluoro-5'-methoxyl group of 2'--[1,1'-biphenyl]-4-base)-3,4-dihydro-2H-pyrans also [2,3-b] pyridin-7-yl) boric acid
To the chloro-2-of 7-(the fluoro-5'-methoxyl group of 2'--[1,1'-biphenyl]-4-base)-3,4-dihydro-2H-pyrans also [2,3-b] pyridine (240mg, 0.649mmol), two (diphenylphosphino) ferrocene-palladium chloride (II) dichloromethane complex (26.5mg of 1,1'-, 0.032mmol), with 4,4,4', 4', 5,5,5', 5'-prestox-2, two (1,3,2-the dioxaborolane) (181mg of 2'-, potassium acetate (191mg, 1.947mmol) is added in dioxane (4mL) solution that nitrogen 0.714mmol) purges.Heat block heats this reactant mixture to 100 DEG C.After 16h, this mixture is poured in NaHCO (saturated aqueous solution, 10mL) also with EtOAc (2x25mL) extraction.The organic layer drying (MgSO) that merges is concentrated.Use the thick residue of gained and without being further purified.
Step 4:(Z)-3-cyclopropyl-3-(2-(the fluoro-5'-methoxyl group of 2'--[1,1'-biphenyl]-4-base)-3,4-dihydro-2H-pyrans also [2,3-b] pyridin-7-yl) acrylic acid methyl ester.
To (2-(the fluoro-5'-methoxyl group of 2'--[1,1'-biphenyl]-4-base)-3,4-dihydro-2H-pyrans also [2,3-b] pyridin-7-yl) boric acid
(76mg; .2mmol); Tetrakis (11.56mg; 10.00 μm ol); (Z)-3-cyclopropyl-3-(((trifluoromethyl) sulfonyl) oxygen base) acrylic acid methyl ester. (54.8mg; KCO (0.20ml, 0.40mmol, the 2N solution in water) is added in dioxane (1.5ml) solution that nitrogen 0.200mmol) purges.Then, this reactant mixture is heated to 100 DEG C by heat block.After 16h, this reaction is cooled to room temperature and pours into NHCl (sat, aq, 10mL).This mixture is extracted with EtOAc (2x10mL).The organic layer drying (MgSO) that merges is concentrated.By HPLC (ISCO120g, 0 to 40%EtOAc/Hex) purification gained residue to provide title compound.
1HNMR(500MHz，CHCl
3-d)：7.55(m，4H)，7.45(d，1H)，7.08(t，1H)，6.95(q，1H)，6.80(m，2H)，5.88(s，1H)，5.35(d，1H)，3.81(s，3H)，3.58(s，3H)，3.00(m，1H)，2.82(d，1H)，2.30(d，1H)，2.15(m，1H)，1.81(m，1H)，0.90(s，2H)，0.70(s，2H).
Step 5:3-cyclopropyl-3-(2-(the fluoro-5'-methoxyl group of 2'--[1,1'-biphenyl]-4-base)-3,4-dihydro-2H-pyrans also [2,3-b] pyridin-7-yl) methyl propionate
To (Z)-3-cyclopropyl-3-(2-(fluoro-5'-methoxyl group-[1 of 2'-, 1'-biphenyl]-4-base)-3,4-dihydro-2H-pyrans also [2,3-b] pyridin-7-yl) acrylic acid methyl ester. (6mg, carrying alumina rhodium (powder, 5% by weight) is added in ethyl acetate (1mL) solution 0.013mmol).Purge this reaction, then backfill hydrogen.This mixture of vigorous stirring under hydrogen balloon.After 16h, this reaction is discharged on lid (hood).Then this reaction is filtered and concentrated filtrate through Celite.By HPLC (ISCO24g, 0 to 50%EtOAc/Hex) purification gained residue to provide title compound.
Step 6:3-cyclopropyl-3-(2-(the fluoro-5'-methoxyl group of 2'--[1,1'-biphenyl]-4-base)-3,4-dihydro-2H-pyrans also [2,3-b] pyridin-7-yl) propanoic acid
To 3-cyclopropyl-3-(2-(the fluoro-5'-methoxyl group-[1 of 2'-, 1'-biphenyl]-4-base)-3,4-dihydro-2H-pyrans also [2,3-b] pyridin-7-yl) methyl propionate (4mg, 8.67 μm of ol) MeOH/THF/ water (3mL, 1:1:1) add LiOH (2.076mg, 0.087mmol) in solution.After 16h, this reaction is poured in saturated NHCl (10mL) also with EtOAc (2x10mL) extraction.The organic layer drying (MgSO) that merges is concentrated.By HPLC (ISCO40g, 0 to 100%EtOAc/Hex) purification gained residue to provide title compound.
By the component I for preparing and II, obtain described diabetes combination of oral medication according to following dosage is composite:
(1) 5-(3-hydroxyl-7-propoxyl group naphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt of 15mg
(2) 3-cyclopropyl-3-(2-(2 '-fluoro-5 '-methoxyl group-[1,1 '-biphenyl]-4-base)-3,4-dihydro-2H-pyrans also [2, the 3-b] pyridin-7-yl) propanoic acid of 30mg
(3) 268mg microcrystalline Cellulose,
(4) 20mg cross-linking sodium carboxymethyl cellulose, and
(5) 5mg magnesium stearate.
The bull C57BLob/ob mice in 11 week age is housed in reverse smooth circular chamber (from 6:00p.m. to 6:00a.m. illumination) with 6/cage, arbitrarily edible Purina Rodent Meal and drinking-water.At the 1st day, get tail blood sample at 8:00am, measure plasma glucose levels.Animal is randomized into matched group and compound group.The meansigma methods of the plasma glucose levels of each group is mated.Then the Orally administered solvent of animal (there is 0.5% carboxymethyl cellulose of 0.2% tween 80) or the compound (30mg/kg) in solvent is given.Every day, to mice administration, amounts to 3 days.At the 4th day, get basal blood specimens.Adopt the concentration of glucose of YSI2700 dual pathways biochemistry analyzer (YellowSpringsInstrumentCo., YellowSprings, OH) analysed for plasma sample, adopt ELISA algoscopy to measure insulin concentration.Test result shows, its concentration of glucose is 80-120mg/dL, its insulin concentration: 4.4 ~ 8.0mmol/L.
Comparative example 1
Containing the component I of 100mg, not containing component I I, all the other conditions are constant, and its concentration of glucose and insulin concentration are all in the scope of embodiment 1.
Comparative example 2
Containing the component I of 50mg, not containing component I I, all the other conditions are constant, and its concentration of glucose is greater than 150mg/dL.
Comparative example 3
Containing the component I I of 100mg, not containing component I, all the other conditions are constant, and its concentration of glucose and insulin concentration are all in the scope of embodiment 1.
Comparative example 4
Containing the component I I of 50mg, not containing component I, all the other conditions are constant, and its concentration of glucose is greater than 150mg/dL.
Above-described embodiment and comparative example explanation, diabetes combination of oral medication of the present invention, it is composite by two kinds of dissimilar active matters, under the prerequisite reaching identical therapeutic effect, the use amount of the active matter of medicine is reduced at least 1/2, when two kinds of active matters that the present invention adopts are used alone, within the scope of equal volume, glucose in blood cannot be reduced in normal range of the present invention, prove to create cooperative effect between two kinds of active matters that the present invention adopts.
Applicant states, the present invention illustrates diabetes combination of oral medication of the present invention by above-described embodiment, but the present invention is not limited to above-mentioned specific components and formula, does not namely mean that the present invention must rely on above-mentioned detailed component and formula could be implemented.Person of ordinary skill in the field should understand, any improvement in the present invention, to equivalence replacement and the interpolation of auxiliary element, the concrete way choice etc. of each raw material of product of the present invention, all drops within protection scope of the present invention and open scope.
Claims (2)
1. a diabetes combination of oral medication, it comprises following component:
(1) 5-(3-hydroxyl-7-propoxyl group naphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt of 10-20mg
(2) 3-cyclopropyl-3-(2-(2 '-fluoro-5 '-methoxyl group-[1,1 '-biphenyl]-4-base)-3,4-dihydro-2H-pyrans also [2, the 3-b] pyridin-7-yl) propanoic acid of 20-30mg
(3) 200-300mg microcrystalline Cellulose,
(4) 10-25mg cross-linking sodium carboxymethyl cellulose, and
(5) 1-8mg magnesium stearate.
2. diabetes combination of oral medication as claimed in claim 1, it is characterized in that, described 5-(3-hydroxyl-7-propoxyl group naphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt and 3-cyclopropyl-3-(2-(2 '-fluoro-5 '-methoxyl group-[1,1 '-biphenyl]-4-base)-3,4-dihydro-2H-pyrans also [2,3-b] pyridin-7-yl) ratio of propanoic acid is less than 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510767710.1A CN105232547A (en) | 2015-11-11 | 2015-11-11 | Anti-diabetic oral drug composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510767710.1A CN105232547A (en) | 2015-11-11 | 2015-11-11 | Anti-diabetic oral drug composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105232547A true CN105232547A (en) | 2016-01-13 |
Family
ID=55030547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510767710.1A Pending CN105232547A (en) | 2015-11-11 | 2015-11-11 | Anti-diabetic oral drug composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105232547A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101687828A (en) * | 2007-06-04 | 2010-03-31 | 诺瓦提斯公司 | Thiadiazole derivatives as antidiabetic agents |
| CN104994848A (en) * | 2013-02-22 | 2015-10-21 | 默沙东公司 | Antidiabetic bicyclic compounds |
-
2015
- 2015-11-11 CN CN201510767710.1A patent/CN105232547A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101687828A (en) * | 2007-06-04 | 2010-03-31 | 诺瓦提斯公司 | Thiadiazole derivatives as antidiabetic agents |
| CN104994848A (en) * | 2013-02-22 | 2015-10-21 | 默沙东公司 | Antidiabetic bicyclic compounds |
Non-Patent Citations (1)
| Title |
|---|
| 万祺 等: "治疗2型糖尿病新靶标及新先导化合物的研究进展", 《中国新药杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104837503B (en) | Treating the Compounds and methods for that the antiport in relevant disease and enterogastric diseases being used to that NHE- to be inhibited to mediate is overloaded with fluid retention or salinity | |
| CN107427527A (en) | Bile acid derivative and its application method as FXR/TGR5 activators | |
| CN102316872A (en) | The bile acid recirculation inhibitor of treatment of obesity and diabetes | |
| TWI749024B (en) | Compounds and their use for reducing uric acid levels | |
| CN104902930A (en) | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | |
| CN102127070A (en) | Pyridine cyclo-derivative | |
| CN103102322B (en) | Oxazole compounds and preparation method thereof, medical composition and its use | |
| US9193756B2 (en) | Adrenomedullin production enhancer | |
| CN104557944B (en) | A kind of hypoglycemic medicine and preparation method thereof | |
| CN105232547A (en) | Anti-diabetic oral drug composition | |
| WO2022111493A1 (en) | Pharmaceutical use of complex of arb metabolite and nep inhibitor in prevention and/or treatment of nephropathy | |
| CN105434434A (en) | Antidiabetic oral drug composition | |
| CN105232543A (en) | Anti-diabetic oral drug composition | |
| CN105287532A (en) | Anti-diabetic orally-administered pharmaceutical composition | |
| WO2015178683A1 (en) | Pharmaceutical composition comprising p-glycoprotein inhibitor and p-glycoprotein substrate drug | |
| CN105287531A (en) | Anti-diabetic orally-administered pharmaceutical composition | |
| CN105193821A (en) | Diabetes mellitus resistant oral medicine composition | |
| CN101863902B (en) | Preparation method and application of 2-substituted phenyl-2-(4,5,6,7-thiophane [3,2-c] pyridine-5(4H)-group) acetic acid (substituted alkyl alcohol) ester | |
| CN105213386A (en) | A kind of diabetes combination of oral medication | |
| CN105232545A (en) | Antidiabetic oral drug composition | |
| CN105193801A (en) | Diabetes mellitus resistant oral medicine composition | |
| CN105287533A (en) | Anti-diabetes oral pharmaceutical composition | |
| CN105213380A (en) | A kind of diabetes combination of oral medication | |
| CN105412095A (en) | Anti-diabetes oral drug composition | |
| CN105287534A (en) | Anti-diabetes oral pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160113 |
|
| WD01 | Invention patent application deemed withdrawn after publication |